Vanda Pharmaceuticals Inc. (VNDA): Cash & Equivalents
$84.85M
As of 2025-12-31
$55.88M
As of 2026-06-30
-14.3%
3-year compound annual growth
+6.8%
5-year compound annual growth
+5.3%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $84.85M | -17.1% | 2026-02-12, Balance as of period end |
| 2024-12-31 | $102.32M | -24.7% | 2026-02-12, Balance as of period end |
| 2023-12-31 | $135.82M | +0.6% | 2025-02-14, Balance as of period end |
| 2022-12-31 | $135.03M | +159.3% | 2024-02-08, Balance as of period end |
| 2021-12-31 | $52.07M | -14.7% | 2023-02-09, Balance as of period end |
| 2020-12-31 | $61.03M | +35.4% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $45.07M | -26.1% | 2021-02-11, Balance as of period end |
| 2018-12-31 | $61.01M | +81.4% | 2020-02-26, Balance as of period end |
| 2017-12-31 | $33.63M | -16.8% | 2019-02-19, Balance as of period end |
| 2016-12-31 | $40.43M | -20.5% | 2018-02-15, Balance as of period end |
| 2015-12-31 | $50.84M | -16.5% | 2018-02-15, Balance as of period end |
| 2014-12-31 | $60.90M | -6.0% | 2017-02-17, Balance as of period end |
| 2013-12-31 | $64.76M | -27.0% | 2016-02-12, Balance as of period end |
| 2012-12-31 | $88.77M | +1.0% | 2015-03-13, Balance as of period end |
| 2011-12-31 | $87.92M | +106.6% | 2014-02-25, Balance as of period end |
| 2010-12-31 | $42.56M | -79.3% | 2013-02-26, Balance as of period end |
| 2009-12-31 | $205.29M | n/a | 2012-03-09, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $84.85M | -17.1% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $134.66M | +11.3% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $112.83M | +33.7% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $29.64M | -57.2% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $238.20M | +93.5% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $184.84M | +256.4% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $287.42M | -48.7% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $54.30M | -39.1% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $222.00M | +48.0% |
Compare VNDA, AMRN, IDYA, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗